In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Changes Possible For FDA’s Quality System Inspection Technique

This article was originally published in The Gray Sheet

Executive Summary

FDA's Quality System Inspection Technique (QSIT) may be revised to give agency investigators more time to review device manufacturers' purchasing controls during facility inspections

You may also be interested in...



Is Pharma Too Introspective To Be Truly Innovative?

The pharmaceutical industry is more diverse today in terms of nationality and culture. However, there is still a lack of other types of diversity, which blocks the proactive inclusion of different perspectives. Raafi-Karim Alidina, a consultant with global diversity and inclusion consultancy Frost Included and the co-author of Building An Inclusive Organisation shares his thoughts. 

Stockwatch: The Victimization Of Big Biotech

Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.

J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling

Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.

UsernamePublicRestriction

Register

LL080237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel